ArticleScientific reports2026
Autoantibodies against nephrin and podocin are associated with disease severity and steroid dependence in adult-onset nephrotic syndrome.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nephrotic syndrome is a glomerular disorder characterized by heavy proteinuria and hypoalbuminemia. Autoantibodies against slit diaphragm proteins such as nephrin and podocin have been identified in subsets of patients, but their prevalence and clinical significance in adult-onset disease are not fully understood. We retrospectively studied 114 adults with biopsy-proven nephrotic syndrome, including minimal change nephrotic syndrome, focal segmental glomerulosclerosis, and phospholipase A2 receptor- and neural epidermal growth factor-like 1-associated membranous nephropathy. Serum anti-nephrin and anti-podocin autoantibodies were quantified using enzyme-linked immunosorbent assays.Anti-nephrin autoantibodies were detected predominantly in minimal change nephrotic syndrome (38.2%) and less frequently in focal segmental glomerulosclerosis (14.3%), but were rare in membranous nephropathy. In contrast, anti-podocin autoantibodies were observed across disease types and were most frequent in neural epidermal growth factor-like 1-associated membranous nephropathy (30.8%). Autoantibody-positive patients presented with more severe nephrotic syndrome, and antibody positivity was associated with a higher incidence of steroid-dependent nephrotic syndrome in exploratory multivariable analyses. In patients with paired samples, autoantibody titers decreased or disappeared in remission.Notably, anti-nephrin antibodies were preferentially associated with MCNS, whereas anti-podocin antibodies were detected across disease entities and may reflect the extent of podocyte injury rather than disease specificity. Moreover, combined assessment of anti-nephrin and anti-podocin antibody status provided improved stratification of baseline disease severity and relapse-prone disease compared with anti-nephrin antibody status alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.